0001437749-22-026595.txt : 20221109 0001437749-22-026595.hdr.sgml : 20221109 20221109161118 ACCESSION NUMBER: 0001437749-22-026595 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20221109 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221109 DATE AS OF CHANGE: 20221109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOLIFE SOLUTIONS INC CENTRAL INDEX KEY: 0000834365 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 943076866 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36362 FILM NUMBER: 221372681 BUSINESS ADDRESS: STREET 1: 3303 MONTE VILLA PARKWAY STREET 2: SUITE 310 CITY: BOTHELL STATE: WA ZIP: 98021 BUSINESS PHONE: 4254011400 MAIL ADDRESS: STREET 1: 3303 MONTE VILLA PARKWAY STREET 2: SUITE 310 CITY: BOTHELL STATE: WA ZIP: 98021 FORMER COMPANY: FORMER CONFORMED NAME: BIOLIFE SOLUTION INC DATE OF NAME CHANGE: 20030113 FORMER COMPANY: FORMER CONFORMED NAME: CRYOMEDICAL SCIENCES INC DATE OF NAME CHANGE: 19920703 8-K 1 bioli20221109_8k.htm FORM 8-K bioli20221109_8k.htm
false 0000834365 0000834365 2022-11-09 2022-11-09
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): November 9, 2022
 
BIOLIFE SOLUTIONS, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
  
001-36362
  
94-3076866
(State or other jurisdiction of
incorporation)
  
(Commission File Number)
  
(IRS Employer Identification No.)
 
3303 Monte Villa Parkway,
Bothell, WA 98021
(Address of principal executive offices) (Zip Code)
 
Registrant’s telephone number, including area code: (425) 402-1400
 
N/A
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading symbol
Name of exchange on which registered
BioLife Solutions, Inc. Common Stock
BLFS
NASDAQ Capital Market
 
 
 
 
Item 2.02         Results of Operations and Financial Condition.
 
On November 9, 2022, BioLife Solutions, Inc. issued a press release announcing financial results and operational highlights for the third quarter ended September 30, 2022. A copy of the press release is furnished as Exhibit 99.1 to this current report on Form 8-K.
 
Item 9.01         Financial Statements and Exhibits.
 
(d) Exhibits
 
Exhibit No.
  
Description
99.1
  
104
  
Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 
 
 
SIGNATURE
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
BioLife Solutions, Inc.
  
     
Date: November 9, 2022
By:
/s/ Troy Wichterman
  
   
Name: Troy Wichterman
Title: Chief Financial Officer
  
 
 
 EX-99.1 2 ex_445071.htm EXHIBIT 99.1 ex_445071.htm

Exhibit 99.1

 

pic1.jpg

 

BioLife Solutions Reports Third Quarter 2022 Financial Results

 

Record revenue of $40.7 million increased 21% over Q3 2021; biopreservation media revenue growth of 50%, validating leading position as a critical cell and gene therapies tool supplier

 

Cash flow from operations of $1.5 million and adjusted EBITDA of $1.4 million

 

Tightens 2022 revenue guidance range reflecting year-over-year growth of 34% to 38% and organic growth of 37% to 40%

 

Conference call begins at 4:30 p.m. Eastern time today

 

 

BOTHELL, Wash. (November 9, 2022) – BioLife Solutions, Inc. (Nasdaq: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapy (CGT) and the broader biopharma markets, today announced financial results for the three and nine months ended September 30, 2022.

 

Mike Rice, Chairman and CEO, commented, “Against a backdrop of several macro headwinds affecting the life science tools industry, our team delivered a strong quarterly performance from our diversified offering of products and services, setting the stage for record full-year revenue. We are tightening our 2022 revenue guidance range and have a bullish outlook for 2023, driven by strong growth expectations from our Cell Processing platform.”

 

“Our high-margin biopreservation media product line, which is recurring consumables revenue, grew 50% over Q3 2021. With our year-to-date results, BioLife has validated its position as a CGT tools leader. We generated record total revenue for Q3 despite a prior year comparable that included significant COVID-related revenue. We continue to diversify our customer base and increase cross-selling success by partnering with customers to drive adoption of multiple platforms, all of which can reduce risk in CGT manufacturing, storage and distribution. It’s important to note that in Q3, 44% of total revenue was from proprietary consumables and 18% was from recurring service revenue, so over 60% of total revenue was from non-capital equipment sales.”

 

Troy Wichterman, CFO, added, “We achieved positive adjusted EBITDA of $1.4 million for the third quarter, with further gains expected in Q4 2022. Although we continue to experience strong demand for our biopreservation media products, we are adjusting the top of our 2022 revenue guidance range to reflect expected shipment delays related to industry-wide supply-chain challenges impacting our cryogenic freezer product line. Any delays are expected to create a backlog of orders that we expect to ship in Q1 2023.”

 

 
 

 

pic1.jpg

 

Operational Highlights

 

 

●

For the third quarter of 2022, we gained 193 new direct customer sites including 14 for biopreservation media, 11 for ThawSTAR® systems, 12 for evo® cold chain management services, 14 for CBS cryogenic freezers and accessories, 114 for Stirling ULT freezers and accessories, 18 for SciSafe® biologic storage services and 10 for Sexton cell processing products.

 

 

●

For the third quarter of 2022, we received 19 new U.S. FDA Drug Master File cross-reference requests, indicating the planned use of CryoStor® or HypoThermosol® in pending CGT clinical trials. To date, we estimate our biopreservation media products have been used in or are planned to be used in 570 customer clinical applications, including 11 approved CGT products and at least 10 therapies with regulatory filings expected to be submitted in 2022 or 2023. We continue to estimate annual biopreservation media revenue per approved commercial application will range from $500,000 to $2 million.

 

 

●

Use of our evo cold chain solution by CGT end customers continued to increase in Q3 2022. Our more than 2,000 courier partner shipments were up 100% over Q3 2021. This adoption validates our belief that the evo platform will increasingly be selected as a class-defining temperature-controlled shipping container and related cloud app by leading CGT companies. We are currently supporting four of the six currently approved CAR T-cell therapies. By mid 2023, we expect the evo platform to be used in all of the currently approved CAR T-cell therapies.

 

 

●

Biological storage services revenue increased significantly in Q3 2022 as we onboarded 18 new customers. Due to increased interest from several global pharma companies and healthcare organizations, we are evaluating several potential sites for our next biorepository location. We expect to finalize a decision in early 2023.

 

 

●

ULT freezer quality continued to improve in Q3 2022 and product lead times were reduced from 12 weeks to zero since the beginning of 2022, despite continued supply chain disruptions. Our field upgrade is about 70% complete and we expect to materially conclude upgrades by the end of the year. Our sales team and distributors continue to drive ULT freezer sales to non-COVID-19 customers, including CGT developers.

 

2 of 13
 

 

pic1.jpg

 

Third Quarter 2022 Financial Results

 

BioLife Solutions is presenting various financial metrics under U.S. Generally Accepted Accounting Principles (GAAP) and as adjusted (non-GAAP). A reconciliation of GAAP to non-GAAP metrics appears at the end of this news release.

 

REVENUE

 

 

●

Total revenue for the third quarter of 2022 was $40.7 million, an increase of $6.9 million, or 21%, from $33.8 million for the third quarter of 2021. Organic revenue growth was 18%. COVID-19 related revenue was approximately 9%, compared with approximately 18% in Q3 2021.

 

 

o

Cell Processing platform revenue was $18.1 million, up $6.6 million, or 57%, over the same period in 2021. Biopreservation media and organic cell processing growth were both 50%.

 

 

o

Freezers and Thaw Systems platform revenue was $15.3 million, down $2.3 million, or (13%), over the same period in 2021, due to a decline in COVID-related revenue which was 23% of platform revenue in Q3 2021 versus only 4% of platform revenue in Q3 2022. This platform was impacted by supply-chain issues that delayed the shipment of several cryogenic freezer orders, which have already shipped or will ship in Q4.

 

 

o

Storage and Storage Services platform revenue was $7.3 million, up $2.6 million, or 56%, over the same period in 2021. Organic growth was 56%. COVID-19 related revenue was approximately 40% for this platform.

 

 

●

Total revenue for the first nine months of 2022 was $117.5 million, an increase of $35.6 million, or 44%, from $81.9 million for the first nine months of 2021. Organic revenue growth was 44%. COVID-19 related revenue was approximately 9%, compared with approximately 16% in 2021.

 

 

o

Cell Processing platform revenue was $48.3 million, up $18.2 million, or 60%, over 2021. Organic growth was 49%.

 

 

o

Freezers and Thaw Systems platform revenue was $49.3 million, up $9.3 million, or 23%, over 2021. Organic growth was 10%. COVID-19 related revenue was approximately 4%.

 

 

o

Storage and Storage Services platform revenue was $19.8 million, up $8.1 million, or 69%, for the total and organic growth over 2021. COVID-19 related revenue was approximately 45%.

 

GROSS MARGIN

 

 

●

Gross margin (GAAP) for the third quarter of 2022 was 31% compared with 25% for the third quarter of 2021. Adjusted gross margin (non-GAAP) for the third quarter of 2022 was 34% compared with 28% for the third quarter of 2021.

 

 

●

Gross margin (GAAP) for the first nine months of 2022 was 31% compared with 36% for the first nine months of 2021. Adjusted gross margin (non-GAAP) for the first nine months of 2022 was 34% compared with 39% for the first nine months of 2021.

 

 

●

The change in gross margin in both periods was primarily due to a shift in product mix after the acquisition of Global Cooling, Inc. (Stirling Ultracold), which has lower gross margins than the remainder of BioLife’s portfolio. The sequential quarterly decline in GAAP and non-GAAP gross margin was primarily due to supplier quality issues impacting yield and customer mix.

 

3 of 13
 

 

pic1.jpg

 

OPERATING EXPENSE

 

 

●

Operating expense (GAAP) for the third quarter of 2022 was $52.2 million compared with $45.0 million for the third quarter of 2021. Adjusted operating expense (non-GAAP) for the third quarter of 2022 was $20.5 million compared with $17.4 million for the third quarter 2021.

 

 

●

Operating expense (GAAP) for the first nine months of 2022 was $212.8 million compared with $98.5 million for the first nine months of 2021. Adjusted operating expense (non-GAAP) for the first nine months of 2022 was $60.3 million compared with $39.5 million for the first nine months of 2021.

 

 

●

The increase in GAAP operating expense for the first nine months of 2022 was primarily due to a non-cash impairment charge of $69.9 million related to the acquired intangible assets of Global Cooling, Inc. (Stirling Ultracold). Adjusted operating expenses (non-GAAP) increased due to the full period of ownership from the acquisition of Global Cooling, Inc. on May 3, 2021, and the acquisition of Sexton Biotechnologies, Inc. on September 1, 2021. In addition, operating expenses increased due to higher accounting costs related to becoming a Large Accelerated Filer and additional headcount to support our growth.

 

OPERATING INCOME/(LOSS)

 

 

●

Operating loss (GAAP) for the third quarter of 2022 was $11.4 million compared with operating loss of $11.2 million for the third quarter of 2021. Adjusted operating loss (non-GAAP) for the third quarter of 2022 was $6.7 million compared with $8.1 million for the third quarter of 2021.

 

 

●

Operating loss (GAAP) for the first nine months of 2022 was $95.3 million compared with operating loss of $16.7 million for the first nine months of 2021. Adjusted operating loss (non-GAAP) for the first nine months of 2022 was $20.2 million compared with $7.5 million for the first nine months of 2021.

 

NET INCOME/(LOSS)

 

 

●

Net loss (GAAP) for the third quarter of 2022 was $10.0 million compared with net income of $79,000 for the third quarter of 2021. Adjusted net loss (non-GAAP) for the third quarter of 2022 was $6.6 million compared with adjusted net loss of $8.3 million for the third quarter of 2021.

 

 

●

Net loss (GAAP) for the first nine months of 2022 was $89.6 million compared with net income of $6.8 million for the first nine months of 2021. Adjusted net loss (non-GAAP) for the first nine months of 2022 was $20.1 million compared with adjusted net loss of $7.8 million for the first nine months of 2021.

 

4 of 13
 

 

pic1.jpg

 

EARNINGS/(LOSS) PER SHARE

 

 

●

Loss per share (GAAP) for the third quarter of 2022 was $0.23 compared with earnings per diluted share of $0.00 for the third quarter of 2021.

 

 

●

Loss per share (GAAP) for the first nine months of 2022 was $2.11 and included a non-cash intangible impairment charge of $1.65 per share. This compared with earnings per diluted share for the first nine months of 2021 of $0.17.

 

ADJUSTED EBITDA

 

●

Adjusted EBITDA, a non-GAAP measure, for the third quarter of 2022 was $1.4 million compared with negative $2.1 million for the third quarter of 2021.
 

●

Adjusted EBITDA, a non-GAAP measure, for the first nine months of 2022 was $2.8 million compared with $4.4 million for the first nine months of 2021.

 

CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES

 

 

●

Cash, cash equivalents, and marketable securities as of September 30, 2022 were $62.1 million compared to $46.6 million as of June 30, 2022. The increase of cash in the third quarter was primarily related to borrowing $20 million upon closure of a term loan agreement and positive cash flow from operations of $1.5 million, offset by the repayment of a separate term loan and capital expenditures.

 

5 of 13
 

 

pic1.jpg

 

2022 Revenue Guidance

 

Management is updating 2022 revenue guidance. Total revenue for 2022 is now expected to range from $160 million to $164 million compared with prior guidance of $160 million to $166 million, and reflects year-over-year growth of 34% to 38% and organic growth of 37% to 40%. COVID-19 related revenue is expected to account for approximately 7% to 8% of total revenue.

 

This revised revenue guidance includes the following platform contributions:

 

 

●

Cell Processing platform: $67.0 million to $68.0 million, an increase of 49% to 51% over 2021 and organic growth of 42% to 43%. This includes biopreservation media and Sexton products. Previous revenue guidance was in a range from $67.0 million to $69.5 million. This modest reduction in the top of the range is due to anticipated supply chain constraints.

 

 

●

Freezers and Thaw Systems platform: $66.0 million to $68.0 million, an increase of 17% to 20% over 2021 and organic growth of 8% to 13%. COVID-19 related revenue is expected to account for 3% of the freezer and thaw systems platform revenue in 2022. This includes ThawSTAR thawing devices, cryogenic liquid nitrogen freezers and ULT Stirling freezers. There continues to be some supply chain risk which could impact this platform in Q1. Previous revenue guidance was in a range from $70.0 million to $71.5 million. This reduction is due to anticipated supply chain constraints.

 

 

●

Storage and Storage Services platform: $27.0 million to $28.0 million, a total and organic increase of 54% to 59% over 2021. COVID-19 related revenue is expected to account for approximately 40% to 45% of the storage and storage services platform revenue. COVID-19 related storage revenue is primarily generated from contracts, including some that extend beyond 2022. Previous revenue guidance was in a range from $23.0 million to $25.0 million. The increase is due to anticipated increased demand for our Storage and Storage Services

 

Although the Company does not provide guidance below the revenue line, BioLife expects positive full year adjusted EBITDA.

 

Conference Call & Webcast

 

Management will discuss the Company's financial results, provide a general business update and answer questions during a conference call and live webcast today at 4:30 p.m. ET (1:30 p.m. PT).

 

To access the webcast, log onto the Investor Relations page of the BioLife Solutions website at https://www.biolifesolutions.com/earnings. In addition, the conference call will be accessible by dialing toll-free (800) 715-9871 for domestic callers or (646) 307-1963 for international callers. The conference ID number is 8988696. A webcast replay will be available approximately two hours after the call ends and will be archived on https://www.biolifesolutions.com/ for 90 days.

 

6 of 13
 

 

pic1.jpg

 

About BioLife Solutions

 

BioLife Solutions is a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy and broader biopharma markets. Our tools portfolio includes our proprietary CryoStor® and HypoThermosol® biopreservation media for shipping and storage, the ThawSTAR® family of automated, water-free thawing products, evo® cold chain management system,  high capacity cryogenic storage freezers, Stirling Ultracold mechanical freezers, SciSafe biologic storage services, and Sexton Biotechnologies cell processing tools. For more information, please visit www.biolifesolutions.com, www.scisafe.com, www.stirlingultracold.com, or www.sextonbio.com and follow BioLife on Twitter.

 

Cautions Regarding Forward Looking Statements

 

Except for historical information contained herein, this press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements concerning the expected financial performance of the Company following the completion of its 2019, 2020 and 2021 acquisitions and giving effect to the COVID-19 pandemic, the Company's ability to implement its business strategy and anticipated business and operations, in particular following its recent acquisitions and the construction and validation of a center of excellence biorepository, the expected synergies between the Company and the companies and products that it has recently acquired, the Company’s ability to realize all or any of the anticipated benefits associated with its recent acquisitions, the Company’s ability to address and resolve ULT freezer issues, the potential utility of and market for the Company's products and services, including the adoption of evo cold chain services by all six currently approved CAR T-cell therapies, and the Company’s ability to cross sell its products and services, guidance for financial results for 2022, including regarding revenue of its recently acquired products, and potential revenue growth and changes in gross margin, adjusted gross margin and adjusted EBITDA margin, and potential market expansion, including with consideration to our recent acquisitions and giving effect to the COVID-19 pandemic, the Company's anticipated future growth strategy, including the acquisition of synergistic cell and gene therapy manufacturing tools and services or technologies, regulatory approvals and/or commercial manufacturing of our customers' products, and potential customer revenue. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including among other things, unexpected costs, charges or expenses resulting from our recent acquisitions, market adoption of the Company’s products (including the Company’s recently acquired products), the ability of our recent acquisitions to be accretive on the Company’s financial results, the ability of the Company to continue to implement its business strategy, uncertainty regarding third-party market projections, market volatility, competition, litigation, the impact of the COVID-19 pandemic and supply chain issues, and those other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

 

Non-GAAP Measures of Financial Performance:

 

To supplement our financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measures of financial performance are included in this release: adjusted gross profit and gross margin, adjusted operating expenses, adjusted operating income/(loss), adjusted net income/(loss), earnings before interest, taxes, depreciation and amortization (EBITDA), and adjusted EBITDA. A reconciliation of GAAP to adjusted non-GAAP financial measures is included as an attachment to this press release. When analyzing the Company's operating results, investors should not consider non-GAAP measures as substitutes for the comparable financial measures prepared in accordance with GAAP.

 

7 of 13
 

 

pic1.jpg

 

 

Media & Investor Relations

 

At the Company

 

Troy Wichterman

Chief Financial Officer

(425) 402-1400

twichterman@biolifesolutions.com

 

 

Investors

 

LHA Investor Relations

Jody Cain

(310) 691-7100

jcain@lhai.com

 

8 of 13
 

 

pic1.jpg

 

BIOLIFE SOLUTIONS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited, amounts in thousands, except share and per share amounts)

 

 

   

Three Months Ended

    

Nine Months Ended

  
   

September 30,

    

September 30,

  

(In thousands, except per share and share data)

  

2022

    

2021

    

2022

    

2021

  
                                 

Product revenue

   $ 33,668     $ 29,201     $ 98,227     $ 70,445  

Service revenue

     4,330       2,250       11,117       6,417  

Rental revenue

     2,749       2,349       8,156       4,989  

Total revenue

     40,747       33,800       117,500       81,851  

Costs and operating expenses:

                                

Cost of product, rental, and service revenue (exclusive of Intangible asset amortization)

     27,009       24,864       77,649       50,968  

Research and development

     3,425       3,219       10,634       8,250  

Sales and marketing

     5,277       4,065       15,583       9,228  

General and administrative

     11,581       10,081       34,128       22,058  

Intangible asset amortization

     2,513       2,525       8,236       5,340  

Acquisition costs

     1       345       18       1,616  

Change in fair value of contingent consideration

     2,346       (140 )     (3,348 )     1,086  

Intangible asset impairment charges

     -       -       69,900       -  

Total operating expenses

     52,152       44,959       212,800       98,546  

Operating loss

     (11,405 )     (11,159 )     (95,300 )     (16,695 )
                                 

Other income (expense), net

                                

Change in fair value of warrant liability

     -       -       -       (121 )

Change in fair value of investments

     697       -       697       -  

Interest income (expense), net

     10       (194 )     (181 )     (331 )

Other expense

     142       (7 )     270       (7 )

Gain on acquisition of Sexton Biotechnologies, Inc.

     -       6,451       -       6,451  

Total other income

     849       6,250       786       5,992  
                                 

Loss before income tax benefit

     (10,556 )     (4,909 )     (94,514 )     (10,703 )

Income tax benefit

     599       4,988       4,937       17,540  

Net (loss) income

   $ (9,957 )   $ 79     $ (89,577 )   $ 6,837  
                                 

Net (loss) income attributable to common shareholders

                                

Basic

   $ (0.23 )   $ 0.00     $ (2.11 )   $ 0.18  

Diluted

   $ (0.23 )   $ 0.00     $ (2.11 )   $ 0.17  

Weighted average shares used to compute earnings (loss) per share attributable to common shareholders:

                                

Basic

     42,647,967       40,911,801       42,376,392       37,435,224  

Diluted

     42,647,967       43,296,470       42,376,392       39,984,923  

 

9 of 13
 

 

pic1.jpg

 

BIOLIFE SOLUTIONS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(Unaudited, amounts in thousands, except per share amounts)

 

 

   

Three Months Ended

    

Nine Months Ended

  
   

September 30,

    

September 30,

  

(In thousands)

  

2022

    

2021

    

2022

    

2021

  
                                 

NET INCOME/(LOSS)

   $ (9,957 )   $ 79     $ (89,577 )   $ 6,837  

Other comprehensive income/(loss)

     (357 )     (166 )     (975 )     (163 )

COMPREHENSIVE INCOME/(LOSS)

   $ (10,314 )   $ (87 )   $ (90,552 )   $ 6,674  

 

 

BIOLIFE SOLUTIONS, INC.

CONDENSED CONSOLIDATED BALANCE SHEET INFORMATION

(Unaudited, amounts in thousands)

 

 

   

September 30,

    

December 31,

  

(In thousands)

  

2022

    

2021

  

Cash, cash equivalents, and marketable securities

   $ 62,140     $ 69,870  

Working capital

     98,926       85,478  

Current assets

     135,874       125,859  

Current liabilities

     36,948       40,381  

Total assets

     487,679       554,057  
                 

Long-term obligations

     42,482       33,539  

Accumulated deficit

     (194,597 )     (105,020 )

Total shareholders' equity

   $ 408,249     $ 480,137  

 

 

BIOLIFE SOLUTIONS, INC.

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS INFORMATION

(Unaudited, amounts in thousands)

 

 

   

Nine Months Ended

  
   

September 30,

  

(In thousands)

  

2022

    

2021

  

Net cash used in operating activities

   $ (16,345 )   $ (3,819 )

Net cash used in investing activities

     (43,223 )     (10,650 )

Net cash provided by (used in) financing activities

     16,941       (673 )

Effects of currency translation

     (176 )     (163 )

Net increase (decrease) in cash, cash equivalents and restricted stock

   $ (42,803 )   $ (15,305 )

 

10 of 13
 

 

pic1.jpg

 

BIOLIFE SOLUTIONS, INC.

RECONCILIATION OF GAAP GROSS PROFIT TO NON-GAAP (ADJUSTED) GROSS PROFIT

(Unaudited, amounts in thousands)

 

 

   

Three Months Ended

    

Nine Months Ended

  
   

September 30,

    

September 30,

  

(In thousands)

  

2022

    

2021

    

2022

    

2021

  

GAAP GROSS PROFIT

   $ 12,442     $ 8,301     $ 36,369     $ 29,075  

GAAP GROSS MARGIN

     31

%

     25

%

     31

%

     36

%
                                 

ADJUSTMENTS TO GROSS PROFIT:

                                

Inventory step-up

     -       365       251       1,130  

Intangible asset amortization

     1,296       635       3,482       1,808  

ADJUSTED GROSS PROFIT

   $ 13,738     $ 9,301     $ 40,102     $ 32,013  

ADJUSTED GROSS MARGIN

     34

%

     28

%

     34

%

     39

%

 

 

BIOLIFE SOLUTIONS, INC.

RECONCILIATION OF GAAP OPERATING EXPENSES TO NON-GAAP (ADJUSTED) OPERATING EXPENSES

(Unaudited, amounts in thousands)

 

 

   

Three Months Ended

    

Nine Months Ended

  
   

September 30,

    

September 30,

  

(In thousands)

  

2022

    

2021

    

2022

    

2021

  

GAAP OPERATING EXPENSES

   $ 52,152     $ 44,959     $ 212,800     $ 98,546  
                                 

ADJUSTMENTS TO OPERATING EXPENSES:

                                

Cost of product, rental, and service revenue

     (27,009 )     (24,864 )     (77,649 )     (50,968 )

Acquisition costs

     (1 )     (345 )     (18 )     (1,616 )

Intangible asset amortization

     (2,513 )     (2,525 )     (8,236 )     (5,340 )

Loss on disposal of assets

     169       (7 )     (88 )     (24 )

Change in fair value of contingent consideration

     (2,346 )     140       3,348       (1,086 )

Intangible asset impairment charges

     -       -       (69,900 )     -  

ADJUSTED OPERATING EXPENSES

   $ 20,451     $ 17,358     $ 60,257     $ 39,512  

 

11 of 13
 

 

pic1.jpg

 

BIOLIFE SOLUTIONS, INC.

RECONCILIATION OF GAAP OPERATING INCOME (LOSS) TO NON-GAAP (ADJUSTED) OPERATING INCOME (LOSS)

(Unaudited, amounts in thousands)

 

 

   

Three Months Ended

    

Nine Months Ended

  
   

September 30,

    

September 30,

  

(In thousands)

  

2022

    

2021

    

2022

    

2021

  

GAAP OPERATING INCOME/(LOSS)

   $ (11,405 )   $ (11,159 )   $ (95,300 )   $ (16,695 )
                                 

ADJUSTMENTS TO OPERATING INCOME:

                                

Inventory step-up

     -       365       251       1,130  

Acquisition costs

     1       345       18       1,616  

Intangible asset amortization

     2,513       2,525       8,236       5,340  

Loss on disposal of assets

     (169 )     7       88       24  

Change in fair value of contingent consideration

     2,346       (140 )     (3,348 )     1,086  

Intangible asset impairment charges

     -       -       69,900       -  

ADJUSTED OPERATING INCOME/(LOSS)

   $ (6,714 )   $ (8,057 )   $ (20,155 )   $ (7,499 )

 

 

BIOLIFE SOLUTIONS, INC.

RECONCILIATION OF GAAP NET INCOME (LOSS) TO NON-GAAP (ADJUSTED) NET INCOME (LOSS)

(Unaudited, amounts in thousands)

 

 

   

Three Months Ended

    

Nine Months Ended

  
   

September 30,

    

September 30,

  

(In thousands)

  

2022

    

2021

    

2022

    

2021

  

GAAP NET INCOME/(LOSS)

   $ (9,957 )   $ 79     $ (89,577 )   $ 6,837  
                                 

ADJUSTMENTS TO NET INCOME/(LOSS):

                                

Inventory step-up

     -       365       251       1,130  

Acquisition costs

     1       345       18       1,616  

Intangible asset amortization

     2,513       2,525       8,236       5,340  

Loss on disposal of assets

     (169 )     7       88       24  

Change in fair value of contingent consideration

     2,346       (140 )     (3,348 )     1,086  

Change in fair value of investments

     (697 )     -       (697 )     -  

Change in fair value of warrant liability

     -       -       -       121  

Gain on acquisition of Sexton Biotechnologies, Inc.

     -       (6,451 )     -       (6,451 )

Income tax benefit

     (599 )     (4,988 )     (4,937 )     (17,540 )

Intangible asset impairment charges

     -       -       69,900       -  

ADJUSTED NET INCOME/(LOSS)

   $ (6,562 )   $ (8,258 )   $ (20,066 )   $ (7,837 )

 

12 of 13
 

 

pic1.jpg

 

BIOLIFE SOLUTIONS, INC.

RECONCILIATION OF GAAP NET INCOME (LOSS) TO NON-GAAP (ADJUSTED) EBITDA

(Unaudited, amounts in thousands)

 

 

   

Three Months Ended

    

Nine Months Ended

  
   

September 30,

    

September 30,

  

(In thousands)

  

2022

    

2021

    

2022

    

2021

  

GAAP NET INCOME/(LOSS)

   $ (9,957 )   $ 79     $ (89,577 )   $ 6,837  
                                 

ADJUSTMENTS:

                                

Interest expense/(income), net

     (10 )     194       163       331  

Income tax benefit

     (599 )     (4,988 )     (4,937 )     (17,540 )

Depreciation(1)

     1,722       1,101       5,045       2,996  

Intangible asset amortization

     2,513       2,525       8,238       5,340  

EBITDA

   $ (6,331 )   $ (1,089 )   $ (81,068 )   $ (2,036 )
                                 

OTHER ADJUSTMENTS:

                                

Share-based compensation (non-cash)

     6,299       4,868       17,671       8,892  

Inventory step-up

     -       365       251       1,130  

Acquisition costs

     1       345       18       1,616  

Loss on disposal of assets

     (169 )     7       88       24  

Change in fair value of contingent consideration

     2,346       (140 )     (3,348 )     1,086  

Change in fair value of investments

     (697 )     -       (697 )     -  

Change in fair value of warrant liability

     -       -       -       121  

Gain on acquisition of Sexton Biotechnologies, Inc.

     -       (6,451 )     -       (6,451 )

Intangible asset impairment charges

     -       -       69,900       -  

ADJUSTED EBITDA

   $ 1,449     $ (2,095 )   $ 2,815     $ 4,382  

 

(1) YTD depreciation addback includes a correction for $684,000 of depreciation not previously reported in BioLife Solutions’s earnings release for the three and six months ended June 30, 2022

# # #

 

13 of 13
 EX-101.SCH 3 blfs-20221109.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 4 blfs-20221109_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 blfs-20221109_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Entity, Emerging Growth Company Title of 12(b) Security Trading Symbol Security Exchange Name Amendment Flag Entity, Central Index Key EX-101.PRE 6 blfs-20221109_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 pic1.jpg begin 644 pic1.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Document And Entity Information
Nov. 09, 2022
Document Information [Line Items]  
Entity, Registrant Name BIOLIFE SOLUTIONS, INC.
Document, Type 8-K
Document, Period End Date Nov. 09, 2022
Entity, Incorporation, State or Country Code DE
Entity, File Number 001-36362
Entity, Tax Identification Number 94-3076866
Entity, Address, Address Line One 3303 Monte Villa Parkway
Entity, Address, City or Town Bothell
Entity, Address, State or Province WA
Entity, Address, Postal Zip Code 98021
City Area Code 425
Local Phone Number 402-1400
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity, Emerging Growth Company false
Title of 12(b) Security BioLife Solutions, Inc. Common Stock
Trading Symbol BLFS
Security Exchange Name NASDAQ
Amendment Flag false
Entity, Central Index Key 0000834365
XML 9 bioli20221109_8k_htm.xml IDEA: XBRL DOCUMENT 0000834365 2022-11-09 2022-11-09 false 0000834365 8-K 2022-11-09 BIOLIFE SOLUTIONS, INC. DE 001-36362 94-3076866 3303 Monte Villa Parkway Bothell WA 98021 425 402-1400 false false false false false BioLife Solutions, Inc. Common Stock BLFS NASDAQ EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 22 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.blfs.com/20221109/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports bioli20221109_8k.htm blfs-20221109.xsd blfs-20221109_def.xml blfs-20221109_lab.xml blfs-20221109_pre.xml ex_445071.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "bioli20221109_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "blfs-20221109_def.xml" ] }, "inline": { "local": [ "bioli20221109_8k.htm" ] }, "labelLink": { "local": [ "blfs-20221109_lab.xml" ] }, "presentationLink": { "local": [ "blfs-20221109_pre.xml" ] }, "schema": { "local": [ "blfs-20221109.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 26, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "blfs", "nsuri": "http://www.blfs.com/20221109", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bioli20221109_8k.htm", "contextRef": "d20228K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://www.blfs.com/20221109/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bioli20221109_8k.htm", "contextRef": "d20228K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20221109/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20221109/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20221109/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document, Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20221109/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document, Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20221109/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity, Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20221109/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity, Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20221109/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity, Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20221109/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity, Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20221109/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity, Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20221109/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20221109/role/statement-document-and-entity-information" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity, Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20221109/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity, File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20221109/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity, Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20221109/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity, Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20221109/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity, Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20221109/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20221109/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20221109/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20221109/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20221109/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20221109/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20221109/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20221109/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20221109/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20221109/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001437749-22-026595-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-22-026595-xbrl.zip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